Pro Pharma Talks

Questions for PP Talks – Covid-19 & Children

1. Rationale?

            a. Symptoms less severe than in adults

            b. Children may carry the virus w/o S/S, but may transfer it

            c. Data is variable and in many cases based on limited groups or on case reports

2. What do we know?

            a. 22% of US population is children

            b. 1.7% are reported cases (similar to China data)

            c. Case breakdown = 

                        i. 10-17 y/o = 60%

                        ii. 1 y/o = 15%

                        iii. 1-4 y/o = 11%

                        iv. 5-9 y/o = 15%

                        v. 57% males

            d. Comps to adults

                        i. Peds experience less fever, cough, SOB -- 73% peds vs. 93% adults

                        ii. Hospitalization – 5.7% peds vs. 10% adults

3. Treatments?

            a. Population at risk – no widespread testing, no testing for mild S/S

            b. Perinatal transmission to neonates – guidelines require mandatory testing of neonates

            c. Infants at higher risk than older children

            d. Extrapolate treatments for adults

                        i. Prevention = hand washing, face masks, social distancing

                        ii. Behavioral changes = target stress, excessive worry, sadness, poor eating habits, unhealthy sleep habits, difficulties with attention and concentration

                        iii. Remdesivir – for hospital, severe disease – available for children through FDA Emergency Use Authorization OR through compassionate use program

4. Risks?

            a. Standard vaccinations and wellness checks

            b. PMIS-TS

Podden och tillhörande omslagsbild på den här sidan tillhör Pro Pharma. Innehållet i podden är skapat av Pro Pharma och inte av, eller tillsammans med, Poddtoppen.